Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia

Inclusion Criteria: * Diagnosis of CLL as defined by the NCI-working group * Previous treatment with standard systemic chemotherapy or immunotherapy. * Disease progression or relapse after treatment. * Indication for treatment as defined by the NCI Working Group Guidelines (Cheson, 1996) * ECOG performance status ≤ 2 * Adequate liver and renal and bone marrow function Exclusion Criteria: * Treatment of CLL with chemotherapy, monoclonal antibody or radiotherapy within 60 days prior to entering the study. Acute toxicities from prior therapy must have resolved to Grade ≤ 1. * Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification * Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of breath, COPD) * Active secondary malignancy or history of other malignancy within the last five years * Active symptomatic fungal, bacterial and/or viral infection including active HIV or viral hepatitis (A, B or C). * Patients who are contraindicated for treatment with rituximab * Diagnosis of prolymphocytic leukemia, hairy cell leukemia, leukemic phase of non-Hodgkin's lymphoma, or other non-B-CLL B-cell malignancy; * T-CLL or other T-cell malignancy